The patented technology consists in an alternate more cost effective process for the preparation of the active pharmaceutical ingredient threo-methylphenidate hydrochloride, a central nervous system stimulant.

Specific process conditions were developed to meet the specific requirements of continuous-flow reactors.

This work fits in the actual context of developing efficient continuous-flow processes for the continuous manufacturing of active pharmaceutical ingredients.